Thursday, December 08, 2016 10:01:03 AM
Yes, startup is accurate. Generally biotech startups place bets on a few potential drugs or therapies that yield huge payoffs...or nothing. Seven Years to get those drugs or therapies to a place where they can be monitized is reasonable.We are 5 years into that timeline with HemaXellerate. If it's too risky for most investors that's OK. I believe we're close to ODD and a SP over a dollar. That crazy to many....until it comes true.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
